Natixis Advisors LLC Increases Stock Position in Gilead Sciences, Inc. $GILD

Natixis Advisors LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% during the 3rd quarter, Holdings Channel reports. The firm owned 646,396 shares of the biopharmaceutical company’s stock after buying an additional 17,725 shares during the period. Natixis Advisors LLC’s holdings in Gilead Sciences were worth $71,750,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GILD. Corundum Trust Company INC purchased a new position in Gilead Sciences during the third quarter worth $26,000. Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences during the second quarter valued at $30,000. MTM Investment Management LLC lifted its holdings in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares in the last quarter. Kilter Group LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $33,000. Finally, Millstone Evans Group LLC boosted its stake in shares of Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 118 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the transaction, the chief executive officer owned 566,698 shares in the company, valued at $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 309,280 shares of company stock worth $43,935,470. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $144.08 on Monday. The business’s fifty day moving average price is $138.29 and its 200 day moving average price is $125.85. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $178.86 billion, a P/E ratio of 21.28, a PEG ratio of 1.89 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period last year, the business posted $1.90 EPS. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a $0.82 dividend. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.68%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Citigroup reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday. Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Mizuho boosted their price target on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Barclays initiated coverage on Gilead Sciences in a report on Friday, February 20th. They set an “equal weight” rating and a $155.00 price objective on the stock. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a research report on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $156.72.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.